



The 6th World Congress on
**Controversies to Consensus in Diabetes,
 Obesity and Hypertension (CODHy)**
 Tel Aviv, Israel, February 21-22, 2018
www.codhy.com codhy@codhy.com

COLOR CODE	PREDIABETES	EARLY TREATMENT	THE LATE STAGE
Wednesday 21 February, 2018			
	HALL A	HALL B	HALL C
09:00-10:30	PLENARY SESSION 1 – DIABETES TOMORROW <ul style="list-style-type: none"> Pharmacologic therapy: What's next? Ralph DeFronzo, USA Precision medicine: Myth or reality? TBC Individualization and big data: Synergy or contradiction? TBC Discussion 		
10:30-11:00	COFFEE BREAK		
11:00-12:30	SESSION 2 – IDENTIFYING SUBJECTS AT RISK <ul style="list-style-type: none"> To screen or no to screen? Jaako Tuomilheto, Finland Genes vs. phenotype Valeriya Lyssenko, Sweden Cost-effectiveness of prevention TBC Discussion 	SESSION 3 – TREATMENT INDIVIDUALIZATION <ul style="list-style-type: none"> Pharmacogenomics TBC Treatment personalization after the CVO trials Enzo Bonora, Italy Technology support: Are we there? Avivit Cahn, Israel Discussion 	SESSION 4 – PREVENTING DIABETIC NEPHROPATHY <ul style="list-style-type: none"> Diabetic CKD: An evolving phenotype Anna Solini, Italy Incretins TBC SGLT2-inhibitors Ofri Mosenzen, Israel Discussion
12:30-13:30	LUNCH		



The 6th World Congress on
**Controversies to Consensus in Diabetes,
 Obesity and Hypertension (CODHy)**
 Tel Aviv, Israel, February 21-22, 2018
www.codhy.com codhy@codhy.com

COLOR CODE	PREDIABETES	EARLY TREATMENT	THE LATE STAGE
Wednesday 21 February, 2018 (Cont.)			
	HALL A	HALL B	HALL C
13:30-15:00	SESSION 5 – PRECIPITATING FACTORS <ul style="list-style-type: none"> Endocrine disruptors TBC Genes and environment TBC The long-term effect of the environment – Epigenetics Charlotte Ling, Sweden Discussion 	SESSION 6 – TREATMENT INITIATION IN T2DM <ul style="list-style-type: none"> The role and meaning of guidelines TBC Treat-to-goal or pathophysiological driven treatment? Ralph DeFronzo, USA Patient/physician empowerment Paolo Pozzilli, Italy Discussion 	SESSION 7 – THE ELDERLY T2DM <ul style="list-style-type: none"> Obesity and sarcopenia Stefano Volpato, Italy How to select anti-hyperglycemic treatment Antonio Ceriello, Spain Injectable Philip Home, UK Discussion
15:00-15:30	COFFEE BREAK		
15:30-17:00	PLENARY SESSION 8 – NEW ANTI-HYPERGLYCEMIC AGENTS AND DIABETES PREVENTION <ul style="list-style-type: none"> DPP4-inhibitors Baptist Gallwitz, Germany GLP-1 RAS Agostino Consoli, Italy SGLT2-inhibitors John Wilding, UK Discussion 		



The 6th World Congress on
**Controversies to Consensus in Diabetes,
 Obesity and Hypertension (CODHy)**
 Tel Aviv, Israel, February 21-22, 2018
www.codhy.com codhy@codhy.com

COLOR CODE	PREDIABETES	EARLY TREATMENT	THE LATE STAGE
Thursday 22 February, 2018			
	HALL A	HALL B	HALL C
09:00-10:30	PLENARY SESSION 9 – WHAT TO TREAT IN T2DM? <ul style="list-style-type: none"> The diabetologist <u>Apostolos Tsapas, Greece</u> The cardiologist <u>Nikolaus Marx, Germany</u> The family physician <u>Xavier Cos Claramunt, Spain</u> Discussion 		
10:30-11:00	COFFEE BREAK		
11:00-12:30	SESSION 10 – PREVENTING TYPE 1 DIABETES <ul style="list-style-type: none"> Antigen immunization TBC Targeting the GI tract TBC Targeting the lymphatic system TBC Discussion 	SESSION 11 - TREATMENT EVOLUTION IN TYPE 1 DIABETES <ul style="list-style-type: none"> New insulins TBC The artificial pancreas: Are we there? <u>Moshe Philip, Israel</u> Beta cell replacement TBC Discussion 	SESSION 12 - DIABETES AND HEART FAILURE <ul style="list-style-type: none"> Diabetic cardiomyopathy <u>Angelo Avogaro, Italy</u> KB and heart function <u>Riccardo Bonadonna, Italy</u> HF and anti-hyperglycemic drugs TBC Discussion
12:30-13:30	LUNCH		



The 6th World Congress on
**Controversies to Consensus in Diabetes,
 Obesity and Hypertension (CODHy)**
 Tel Aviv, Israel, February 21-22, 2018
www.codhy.com codhy@codhy.com

COLOR CODE	PREDIABETES	EARLY TREATMENT	THE LATE STAGE
Thursday 22 February, 2018 (Cont.)			
	HALL A	HALL B	HALL C
13:30-15:00	SESSION 13 – FIGHTING OBESITY <ul style="list-style-type: none"> Obesity: A disease or a condition? <u>Dror Dicker, Israel</u> Pharmacological and non-pharmacological treatment of obesity: Present and future <u>Luc Van Gaal, Belgium</u> Metabolic surgery for diabetes prevention? TBC Discussion 	SESSION 14 – BE AWARE OF.... <ul style="list-style-type: none"> Drug safety and efficacy <u>Boaz Hirshberg, USA</u> Hypoglycaemia <u>Simon Heller, UK</u> SGLT2 and DKA TBC Discussion 	SESSION 15 – RESIDUAL CV RISK IN DIABETES <ul style="list-style-type: none"> Non-HDL cholesterol <u>Alberto Zambon, Italy</u> PCSK9 inhibitors TBC How low we want LDL- Cholesterol? Big data: TBC RCT data: <u>Eran Leitersdorf, Israel</u> Reverse cholesterol transport TBC Discussion
15:00-15:30	COFFEE BREAK		
15:30-17:00	PLENARY SESSION 16 – NEW PLAYERS IN T2DM <ul style="list-style-type: none"> NAFLD/NASH <u>Ran Oren, Israel</u> Microbioma TBC CVOT- what's next? <u>Eberhard Standl, Germany</u> Discussion 		